Menarini brings oral SERD to Europe with Orserdu okay

Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the

Sumitomo ups ante and wins support for Myovant takeover

A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a takeover, after its first was rejected.

Neurocrine Bio agrees $57m takeover of UK biotech Diurnal

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its the

Merck makes another bioelectronics play, partnering with Inn...

Merck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia to develop neurostimulator devices for treating chronic diseases.

Carbon Health buys virtual diabetes clinic firm Steady Healt...

US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health.

EMA starts review of Xtandi in hormone-sensitive prostate ca...